MASH Peptide Therapies

Survodutide for MASH: The Dual Agonist Liver Data

Survodutide's phase 2 NEJM trial showed 62% of patients achieved MASH improvement without fibrosis worsening. Here's how the GLP-1/glucagon dual agonist works.